Literature DB >> 19951903

MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.

QiQi Zhou1, Wiley W Souba, Carlo M Croce, G Nicholas Verne.   

Abstract

BACKGROUND: The molecular mechanisms underlying the pathophysiology of irritable bowel syndrome (IBS) are poorly understood. One mechanism may involve increased intestinal permeability that is reversed with glutamine supplementation. Our goal was to evaluate the expression of glutamine synthetase and its complementary miRNA in blood microvesicles and gut tissues of IBS patients with increased intestinal membrane permeability.
METHODS: We evaluated 19 diarrhoea-predominant IBS patients and 10 controls for intestinal membrane permeability using the lactulose/mannitol method. miRNA expression was evaluated in blood microvesicles and gut tissue. To further confirm the relationship between miRNA and glutamine synthetase expression, cell culture experiments were conducted. Glutamine synthetase was also evaluated in the gut tissues of patients.
RESULTS: A subset of patients with IBS (8/19, 42%) had increased intestinal membrane permeability and decreased glutamine synthetase expression compared to patients with IBS normal membrane permeability, and to controls. Expression of miR-29a was increased in blood microvesicles, small bowel and colon tissues of IBS patients with increased intestinal membrane permeability. Increased intestinal permeability was modulated by miR-29a which has a complementary site in the 3'-UTR of the GLUL gene.
CONCLUSIONS: The results support the conclusion that GLUL regulates intestinal membrane permeability and miR-29a regulates both GLUL and intestinal membrane permeability. The data suggests that miR-29a effects on intestinal membrane permeability may be due to its regulation of GLUL. Targeting this signalling pathway could lead to a new therapeutic approach to the treatment of patients with IBS, especially because small molecules that mimic or inhibit miRNA-based mechanisms are readily available.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951903      PMCID: PMC2891786          DOI: 10.1136/gut.2009.181834

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  53 in total

Review 1.  The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness.

Authors:  V S Klimberg; W W Souba
Journal:  Surg Annu       Date:  1990

2.  Inhibition of glutamine synthetase decreases proliferation of cultured rat intestinal epithelial cells.

Authors:  V DeMarco; K Dyess; D Strauss; C M West; J Neu
Journal:  J Nutr       Date:  1999-01       Impact factor: 4.798

3.  Immunoreactivity of the Rho(D) antigen in cytoskeleton-free vesicles.

Authors:  E J Victoria; M J Branks; S P Masouredis
Journal:  Transfusion       Date:  1987 Jan-Feb       Impact factor: 3.157

4.  Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer.

Authors:  S Yoshida; M Matsui; Y Shirouzu; H Fujita; H Yamana; K Shirouzu
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

Review 5.  Irritable bowel syndrome. Streamlining the diagnosis.

Authors:  G N Verne; J J Cerda
Journal:  Postgrad Med       Date:  1997-09       Impact factor: 3.840

Review 6.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

7.  The differing effects of acute and chronic alcohol on gastric and intestinal permeability.

Authors:  A Keshavarzian; J Z Fields; J Vaeth; E W Holmes
Journal:  Am J Gastroenterol       Date:  1994-12       Impact factor: 10.864

8.  Isolation and characterization of large (0.5 - 1.0 micron) cytoskeleton-free vesicles from human and rabbit erythrocytes.

Authors:  K S Leonards; S Ohki
Journal:  Biochim Biophys Acta       Date:  1983-03-09

Review 9.  The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection.

Authors:  W W Souba; V S Klimberg; D A Plumley; R M Salloum; T C Flynn; K I Bland; E M Copeland
Journal:  J Surg Res       Date:  1990-04       Impact factor: 2.192

10.  Visceral and somatic hypersensitivity in a subset of rats following TNBS-induced colitis.

Authors:  QiQi Zhou; Donald D Price; Robert M Caudle; G Nicholas Verne
Journal:  Pain       Date:  2007-05-03       Impact factor: 6.961

View more
  101 in total

Review 1.  IBS: An epigenetic perspective.

Authors:  Timothy G Dinan; John Cryan; Fergus Shanahan; P W Napoleon Keeling; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

2.  Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls.

Authors:  Archana S Rao; Michael Camilleri; Deborah J Eckert; Irene Busciglio; Duane D Burton; Michael Ryks; Banny S Wong; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

3.  Computational functional genomics based analysis of pain-relevant micro-RNAs.

Authors:  Jörn Lötsch; Ellen Niederberger; Alfred Ultsch
Journal:  Hum Genet       Date:  2015-09-18       Impact factor: 4.132

4.  Dysregulation of microRNA biogenesis in the small intestine after ethanol and burn injury.

Authors:  Niya L Morris; Adam M Hammer; Abigail R Cannon; Robin C Gagnon; Xiaoling Li; Mashkoor A Choudhry
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-04-09       Impact factor: 5.187

5.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 6.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 7.  Novel therapeutic agents in neurogastroenterology: advances in the past year.

Authors:  M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2014-06-23       Impact factor: 3.598

Review 8.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

9.  Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution.

Authors:  Arseima Y Del Valle-Pinero; Hendrick E Van Deventer; Nicolaas H Fourie; Angela C Martino; Nayan S Patel; Alan T Remaley; Wendy A Henderson
Journal:  Clin Chim Acta       Date:  2013-01-14       Impact factor: 3.786

10.  Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism.

Authors:  Anuradha Kalani; Pradip K Kamat; Anastasia Familtseva; Pankaj Chaturvedi; Nino Muradashvili; Nithya Narayanan; Suresh C Tyagi; Neetu Tyagi
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-07       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.